Structural basis of the cysteinyl leukotriene receptor type 2 activation by LTD4

M Mengting Jiang (Lingang Laboratory) Y Youwei Xu (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) X Xiaodong Luan (Department of Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science) K Kai Wu (BNLMS, College of Chemistry and Molecular Engineering) Z Zhen Li H H. Eric Xu S Shuyang Zhang (Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine) Y Yi Jiang W Wanchao Yin (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences)

Abstract

The G protein–coupled cysteinyl leukotriene receptor CysLT2R plays intricate roles in the physiology and pathogenesis of inflammation-related processes. It has garnered increasing attention as a potential therapeutic target for atopic asthma, brain injury, central nervous system disorders, and various types of cancer. In this study, we present the cryo-electron microscopy structure of the cysteinyl leukotriene D4 (LTD4)-bound human CysLT2R in complex with a Gα q protein, adopting an active conformation at a resolution of 3.15 Å. The structure elucidates a spacious polar pocket designed to accommodate the two branched negative ends of LTD4 and reveals a lateral ligand access route into the orthosteric pocket located on transmembrane domain helix (TM) 4 and 5. Furthermore, our findings highlight the crucial role of transmembrane domain helix 3 in sensing agonist moieties, representing the pivotal mechanism of receptor activation for both CysLT1R and CysLT2R. Collectively, the insights derived from our structural investigation establish a foundation for comprehending CysLT2R activation by its endogenous ligand LTD4, offering a rational basis for the design of drugs targeting CysLT2R.

Article Details

Volume / Issue Vol. 122, Issue 15
Published April 15, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (9)

M

Mengting Jiang

Lingang Laboratory

Y

Youwei Xu

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

X

Xiaodong Luan

Department of Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science

K

Kai Wu

BNLMS, College of Chemistry and Molecular Engineering

Z

Zhen Li

H

H. Eric Xu

S

Shuyang Zhang

Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine

Y

Yi Jiang

W

Wanchao Yin

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences